BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non–Small Cell Lung Cancer

Journal of Clinical Oncology 2026

View at publisher

Authors: Jordi Remon, Tina Cascone, Solange Peters

DOI: 10.1200/jco-25-02696

Cited by: 4

References: 18

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies

References 18